



GIG
CYMRU
NHS
WALES

Cyd-bwyllgor
Comisiynu
Joint Commissioning
Committee

NHS Wales Joint Commissioning Committee (JCC)

Financial Position Report

Financial Year

2024/25



Financial Month

6



Author: Acting Assistant Director of Finance & Information - Sandy Tallon

Executive Lead: Director of Finance & Information - Stacey Taylor

Date Produced: 9 October 2024



Report Contents

Area	Page Number(s)
Background/Introduction	3
Finance Summary	4
Risks/Opportunities	5
Commissioner Overview	6
Welsh Provider Overview	7
Other Provider Areas Overview	8
Savings	9
Income/PSPP/Actions Notes	10
Confirmation of Report	11
Glossary	12



Annual Budget £'000	Budget to date £'000	Spend to date £'000	Variance to date £'000	Forecast Outturn £'000	Forecast Variance £'000
£1,141,529	£570,765	£574,541	£3,776	£1,147,168	£5,639

The reported position is based on the following:

The overall year-to-date JCC position at month 6 is an **overspend of £3.776m**, with a forecast **year end overspend of £5.639m**. The financial position is reported against the 2024/25 baselines following approval of the WHSSC and EASC 2024-27 Integrated Commissioning Plans (ICP) by their Joint Committees on 19th March 2024, which are now merged into the new JCC. The remit of the JCC is to deliver a plan for Health Boards within an overall financially balanced position. However, the composite individual positions are important and are dealt with in this financial report, together with consideration of corrective actions as the need arises.

- NHS Wales Providers – based on month 5 and year-end forecast data received from Providers. Some adjustments to the provider year-end forecasts have been made by the JCC team in relation to specific areas requiring review during 2024/25 e.g. Cardiac Surgery / TAVI's.
- NHS England Providers – based on month 5 data where received from providers, or on on 5/12ths of 2023/24 outturn positions with inflationary uplift provisions.
- Mental Health & IPFR – live patient data on agreed placements as at the end of the month, plus funding approvals and purchased block bed capacity.

Please note that the year-end forecast overspend is currently £5.6m, and would be £7.4m if extrapolated from the M6 position. Therefore, further mitigations are required to deliver the approved plans to break-even.

Risks to the position (see page 5 for further detail):

The adopted JCC plans were based on the Month 8 2023/24 financial position, and set in the context of a baseline plan. The movement since this presents further risk and challenge in delivering the 2024/25 plan. These include:

1. Additional TAVI activity, in line with the reduced Cardiac Surgery activity. The Cardiac savings have been taken against the Savings target, leaving the TAVI spend exposed until the Cardiac Review can release fixed costs. The Cardiff and Swansea provider year-end forecasts have been reduced by £1m each, and kept to the to-date positions. An SBAR has been received from one provider and will be discussed through the JCC Senior Leaders Group.
2. Kidney Network - overall risk of £0.5m across the board on the renal budgets.
3. In-year financial pressures in certain areas, including ALAS, Gender reassignment, Welsh Kidney Network and various Nice/drug spends. The relevant providers have been asked for detailed projections and spend backing. Developments schemes slippage has been used against the position to date, and are being assessed for potential start dates, which would reduce this avenue of support.
4. Please note the previously reported risks of the Red Savings schemes have now been badged against Development slippage, and is therefore included in the reported position.

Governance & Contracting

Financial variation is distributed back to Health Boards using the established risk sharing framework which was agreed by Joint Committee and implemented from April 2019. This is based predominantly on a 2-year average utilisation calculated on the latest available complete year's data. Due to the nature of highly specialist, high cost and low volume services, a number of areas will continue to be risk shared on a population basis to avoid volatility in individual commissioner's position. Due to COVID and block contracting arrangements the current utilisation shares are based on a 2-year average of 2018/19 and 2019/20 activity. It was agreed to update the risk share during 2024/25.

The Finance Working Group has been re-established under the JCC, and Terms of Reference shared with Directors of Finance, with representatives requested. The first meeting took place on August 2nd, and will continue monthly.

JCC Finance Summary

Financial Year

Financial Month

Multiple selecti... ▾

6 ▾

Area	Annual Budget £'000	Budget to date £'000	Spend to date £'000	Variance to date £'000	Forecast Outturn £'000	Forecast Variance £'000
[-] NHS Wales	£870,266	£435,133	£440,333	£5,200	£879,215	£8,949
Cardiff & Vale	£312,694	£156,347	£160,264	£3,917	£319,294	£6,600
WAST	£276,140	£138,070	£138,070	-	£276,140	-
Swansea Bay	£139,195	£69,597	£71,604	£2,007	£142,032	£2,837
Velindre	£63,334	£31,667	£31,321	(£346)	£62,988	(£346)
Betsi Cadwaladr	£51,102	£25,551	£25,173	(£378)	£50,960	(£142)
Aneurin Bevan	£13,489	£6,745	£6,745	-	£13,489	-
Cwm Taf Morgannwg	£12,094	£6,047	£6,047	-	£12,094	-
Hywel Dda	£2,219	£1,110	£1,110	-	£2,219	-
[+] Non Welsh SLA	£145,013	£72,507	£73,280	£773	£145,649	£636
[+] IPFR	£44,873	£22,436	£25,041	£2,604	£49,739	£4,866
[+] Mental Health	£43,928	£21,964	£21,372	(£592)	£41,643	(£2,285)
[+] Developments	£28,045	£14,022	£9,415	(£4,608)	£23,756	(£4,289)
[+] Direct Running Costs	£9,540	£4,770	£4,563	(£207)	£9,350	(£190)
[+] IVF	£5,530	£2,765	£2,645	(£120)	£5,058	(£472)
[+] Renal	£4,335	£2,168	£2,142	(£26)	£4,259	(£76)
[+] Releases	-	-	(£1,500)	(£1,500)	-£1,500	(£1,500)
[+] Savings	(£10,000)	(£5,000)	(£2,750)	£2,250	-£10,000	-
JCC Total Expenditure	£1,141,529	£570,765	£574,541	£3,776	£1,147,168	£5,639

The overall year-to-date JCC position at month 6 is an **overspend of £3.776m**, with a forecast **year end overspend of £5.639m**. This is mainly driven by Cardiology (specifically TAVI's) and ALAS in Welsh providers.

For **CVUHB & SBUHB**, the reported position is based on August data but the year-end forecasts for TAVI has been amended from the provider returns to show the to-date position, pending the Cardiac Review.

For the **non-Welsh SLAs**, the position includes £2m forecast overspends each on 2 providers, mitigated by ICP funding. WG have been asked to clarify the 24/25 wage award funding.

The **Savings** schemes are currently categorised as £5.5m under green and amber schemes, **with the remaining red schemes being covered from Developments slippage**. All identified schemes have a dedicated Executive, Planning and Finance lead to monitor and track delivery throughout the year. In addition, **Developments funding** is continually being assessed to identify any further possible slippage e.g. recruitment to new posts.

IPFR spend is being examined as a deep dive every month. The overall IPFR position includes £2.2m overspends on ERT and Eculizumab drugs, and £2.2m on HPN homecare drugs. There is a further £1.5m overspend on general IPFR approvals, partially covered by £2m NICE drugs funding cover as funded in the ICP.

Route to Breakeven - work has been done internally with full integration with Health Boards, with a presentation to the JCC on September 17th. A follow up session around options for Health Boards is to be held on October 15th, and work will continue around analysing the financial position.

RISKS

Risks include:

- **Cardiology TAVI costs at both Cardiff & Vale and Swansea Bay providers - £2m has been removed from the provider year-end forecasts pending the Cardiac Review outcomes.** There is increasing demand for this procedure, as agreed by Management Group in December 2023, and further work remains to be done within the overall Cardiac Surgery rebasing work, including work on the Cardiac project Phase 2; this could free up significant fixed costs of around £5m. Note an SBAR has been received from one provider and will be discussed by the JCC Senior Leaders Group
- **The Welsh Kidney Network has increased costs in relation to growth and inflation.** This risk is a further £0.5m at this point.
- **Overspends and red Savings schemes have been covered by recurring and non-recurring slippage on Developments,** This poses a risk if/when these start to be spent later in the year.
- **NHS England** - confirmation has been requested from Welsh Government around fully funding the 24/25 wage award of English contracts.
- **Savings non-performance** relating to red schemes to be identified in-year - **removed in M6 in relation to Development slippage**
- **Plastic Surgery costs relating to treating patients waiting over 104 weeks - removed in light of the WG/provider discussions**
- **Home Parenteral Nutrition** - homecare contracts have been re-procured. Previously there is a risk reported of overspending if all patients were placed on the most expensive framework of £0.9m. **This has been deleted in M6 as the HPN forecast overspend is now fully reported within the position.** The commissioning team has developed a plan to mitigate risk and seek efficiency opportunities, particularly in the nursing support costs, and this will be monitored.
- **Gender reassignment costs continue to rise, as part of the UK service. This risk has been removed** as the additional charges have been fully reflected in the financial position.
- **Velindre - Health Boards are reminded to report their full Velindre risk** pending the non-specialist funding transfer back to them. The paper was taken through the Finance Working Group on Sept 16th and will be with Management Group on Oct 24th

Other areas of risk to be closely monitored in-year where there are notable year-end forecast variances already in the position:

Top 10 Forecast Overspends by Provider & Service	EOYF Variance £'000
Liverpool Heart and Chest Hospital NHS Foundation Trust	£2,200
Walton Centre NHS Foundation Trust	£2,200
IPFR - Home Parenteral Nutrition (HPN) - Drugs	£2,184
Cardiff & Vale ALAS	£1,900
IPFR - Eculizumab (A.H.U.S)	£1,616
IPFR - Enzyme Replacement Therapy	£1,437
Swansea Bay TAVI	£1,315
Adult Mental Health (excl ED) Gender	£1,313
Cardiff & Vale Cardiac Surgery-TAVI	£1,202
Cardiff & Vale NICE / High Cost Drugs	£805
Total	£16,171

OPPORTUNITIES

Opportunities are being explored across various areas, including product procurement/medicines management. An update will be provided in future reports.

- Clinical Immunology - audit of policy adherence. The provider has also been queried around passing through new drugs prices from April
- Repatriation of Cardiac devices as per local investment - ABUHB specifically
- Slippage on Development monies has been utilised in the position to date - note in M6 this has now been badged against Savings scheme slippage
- All recent Funding Releases have been quantified to identify possible slippage eg. recruitment to new posts.
- Cardiac Surgery Phase 2 project - potential to free up fixed costs of around £5m
- Review of Balance sheet accruals from 2023/24 - **£1m estimate**

Commissioner Overview

Financial Year

Multiple selecti... ▾

Financial Month

6 ▾

Budgeted Income £'000	ABUHB	BCUHB	CTMUHB	CVUHB	HDUHB	PTHB	SBUHB	Total
Income	£215,789	£249,265	£160,723	£184,988	£135,277	£56,600	£138,887	£1,141,530

Share of Forecast Year-end Variance by Area £'000	ABUHB	BCUHB	CTMUHB	CVUHB	HDUHB	PTHB	SBUHB	Total Forecast Variance
NHS Wales	£1,982	£555	£1,499	£1,400	£1,524	£292	£1,700	£8,951
IPFR	£1,132	£846	£772	£1,056	£388	£245	£426	£4,864
Non Welsh SLA	(£138)	£1,183	(£150)	(£163)	(£123)	£214	(£187)	£636
Savings	-	-	-	-	-	-	-	-
Renal	(£14)	(£17)	(£11)	(£11)	(£10)	(£3)	(£9)	(£76)
Direct Running Costs	(£35)	(£43)	(£26)	(£33)	(£21)	(£9)	(£23)	(£190)
IVF	(£128)	£140	(£93)	(£203)	(£83)	£12	(£117)	(£472)
Releases	(£281)	(£334)	(£213)	(£238)	(£184)	(£63)	(£186)	(£1,500)
Mental Health	(£665)	(£390)	(£220)	(£201)	(£190)	(£257)	(£363)	(£2,285)
Developments	(£863)	(£607)	(£656)	(£945)	(£510)	(£150)	(£557)	(£4,287)
Total Share of Year-End Variance	£990	£1,332	£903	£661	£791	£279	£683	£5,640

2024/25	£216,780	£250,597	£161,626	£185,650	£136,069	£56,879	£139,570	£1,147,170
---------	----------	----------	----------	----------	----------	---------	----------	------------

Share of Year-to-date Position £000	ABUHB	BCUHB	CTMUHB	CVUHB	HDUHB	PTHB	SBUHB	Total
	£517	£1,525	£228	£122	£492	£340	£552	£3,776

This page provides a breakdown of how the JCC budget is funded by the seven Health Boards.

Any over/under spend is returned to Commissioners based on the risk sharing framework which was agreed by Joint Committee and implemented from April 2019. This is currently based predominantly on a 2-year average of **2018/19 and 2019/20 activity**. It was agreed to update utilisation for 2020/21 and 2021/22 activity would be too volatile given the downturn in activity due to COVID-19, but the intention is to **update these during 2024/25**.

This table highlights the current trajectory to Commissioner positions, by area, based on current year-end forecasts.

This table to the left reports the position at the current month.

Welsh Provider Overview

Financial Year

Financial Month

Multiple selecti... ▾

6 ▾

Provider	Annual Budget £'000	Budget to date £'000	Spend to date £'000	Variance to date £'000	Forecast Year End Outturn £'000	Forecast Variance £'000
Aneurin Bevan	£13,489	£6,745	£6,745	-	£13,489	-
Betsi Cadwaladr	£51,102	£25,551	£25,173	(£378)	£50,960	(£142)
Cardiff & Vale	£312,694	£156,347	£160,264	£3,917	£319,294	£6,600
Cwm Taf Morgannwg	£12,094	£6,047	£6,047	-	£12,094	-
Hywel Dda	£2,219	£1,110	£1,110	-	£2,219	-
Swansea Bay	£139,195	£69,597	£71,604	£2,007	£142,032	£2,837
Velindre	£63,334	£31,667	£31,321	(£346)	£62,988	(£346)
WAST	£276,140	£138,070	£138,070	-	£276,140	-
Welsh Provider Total	£870,266	£435,133	£440,333	£5,200	£879,215	£8,949

For ref: Total Welsh Provider prior year outturn (excl. WAST) £800,681

The **Welsh SLA** provider position at month 6 is an **overspend of £5.200m**, with a forecast year end variance of **£8.949m**.

LTA Agreements:

All JCC/NHS Wales contracts have been agreed, with all the Month 5 contract monitoring reflecting the new 24/25 currencies.

For CVUHB & SBUHB, the reported position is based on August data but the TAVI year-end forecasts for have been amended from the provider return to reflect the to-date position, pending the Cardiac Review.

To note:

- The transfer from the JCC to Health Boards of the non-specialist activity and NICE drugs through Velindre had been agreed in principle for some time, but not actioned yet; a formal paper was taken to the Finance Working Group on Sept 16th, and will be taken to Management Group on Oct 24th.

Top 10 Drivers of Variance to date by Provider & Service £'000

- Swansea Bay TAVI
- Cardiff & Vale Cardiac Surgery-TAVI
- Cardiff & Vale ALAS
- Cardiff & Vale Paeds Respiratory Equip...
- Cardiff & Vale NICE / High Cost Drugs
- Cardiff & Vale Clinical Immunology
- Swansea Bay Renal
- Cardiff & Vale Home TPN
- Cardiff & Vale INR Devices
- Cardiff & Vale Percutaneous Mitral valv...

Swansea Bay TAVI	Cardiff & Vale ALAS	Cardiff &...	Swansea ...
£1,315	£843	£299	£298
Cardiff & Vale Cardiac Surgery-TAVI	Cardiff & Vale Paeds Respi...	Cardiff & ...	Cardiff ...
£1,202	£375	£267	£247
	Cardiff & Vale NICE / High...	Cardiff & Vale Percuta...	
	£318	£245	

The visual to the left highlights the **main drivers of the reported overspends** to date by Provider and Service. This is only based on data to month 5 and will be continually reviewed to assess the risk to the position. Background to some of the overspends include:

- Swansea Bay and Cardiff & Vale/TAVI - overperformance against the old contracts; this will be updated in the new contract rebasing as agreed in the MG paper in December 2023.
- Cardiff & Vale/ALAS - stock adjustments and contract mechanisms; further detail awaited.
- Cardiff & Vale/Paeds Respiratory Equipment - a one-of purchase of £145k was made in M5.
- Cardiff & Vale/NICE & High Cost Drugs - costs above baseline particularly within Tobi (Cystic Fibrosis).
- Cardiff & Vale/Immunology (£299k) - cost pressures, particularly within homecare, driven by natural volatility in the service.

Provider Overview: Other

Financial Year

Financial Month

Multiple selecti... ▾

6 ▾

Area	Annual Budget £'000	Budget to date £'000	Spend to date £'000	Variance to date £'000	Forecast Outturn £'000	Forecast Variance £'000
⊕ Non Welsh SLA	£145,013	£72,507	£73,280	£773	£145,649	£636
⊕ IPFR	£44,873	£22,436	£25,041	£2,604	£49,739	£4,866
⊕ Mental Health	£43,928	£21,964	£21,372	(£592)	£41,643	(£2,285)
⊕ Developments	£28,045	£14,022	£9,415	(£4,608)	£23,756	(£4,289)
⊕ Direct Running Costs	£9,540	£4,770	£4,563	(£207)	£9,350	(£190)
⊕ IVF	£5,530	£2,765	£2,645	(£120)	£5,058	(£472)
⊕ Renal	£4,335	£2,168	£2,142	(£26)	£4,259	(£76)
⊕ Releases		-	(£1,500)	(£1,500)	-£1,500	(£1,500)
⊕ Savings	(£10,000)	(£5,000)	(£2,750)	£2,250	-£10,000	-
Total Non-NHS Wales contracts	£271,263	£135,632	£134,207	(£1,424)	£267,953	(£3,310)

Direct Running Costs:

The **DRC position** for the NWJCC team at month 6 reports a year to date **underspend of £0.207m**, with a **forecast year end underspend of £0.190m**.

There is some non-recurring project team funding to be agreed with Welsh Government; any funding not yet agreed is not reflected in the financial position.

Non Welsh SLAs:

The **Non Welsh SLA** provider position at month 6 is an **overspend of £0.773m**, with a forecast **year-end overspend of £0.636m**.

The reported position is based on month 5 data where received from providers, or on on 5/12ths of 2023/24 outturn positions with inflationary uplift provisions.

To note, included in the ICP is a **£1m savings target relating to NHS England referral management** (see savings section). This is currently badged as red.

The JCC will work collaboratively with Health Boards in the coming months to provide information enabling discussions around options and choices.

Mental Health:

The **Mental Health** position at month 6 is an **underspend of (£0.592m)**, with a forecast year end **underspend of (£2.285m)**.

The JCC finance team have worked extensively on the enhanced observation approvals and processes, leading to a reducing trajectory to year-end. However pressures have been reported in M6 within Forensic MH, eating disorders and gender.

Included in the ICP is a **£1m savings target relating to the Mental Health strategy** (see savings section of report), which is currently reported as being achieved.

Individual Patient Funding Requests (IPFR):

The **IPFR position** at month 6 reports a **year to date overspend of £2.604m**, with a **forecast year end overspend of £4.866m**.

The year-end forecast includes £2.2m in relation to HPN, £1.5m in relation to general IPFR approvals and £1.4m in relation to Enzyme Replacement Therapy.

The general IPFR position includes an unusual number of high-cost individual approvals within the first few weeks of this financial year. A deep dive reconciliation of the approval amounts across annual and one-off approvals is being completed monthly internally. The IPFR team are assessing the overall position, as well as several ideas about reducing spend.

Heading	Annual Budget £'000	Budget to date £'000	Savings reported to date £'000	Variance to date £'000	Forecast Outturn £'000	Forecast Variance £'000
<input checked="" type="checkbox"/> Savings	(£10,000)	(£5,000)	(£2,750)	£2,250	-£10,000	-
Additional schemes to be worked through	(£3,000)	(£1,500)	(£1,012)	£488	-£3,000	-
24/25 Medicines Management	(£2,000)	(£1,000)	(£213)	£787	-£2,000	-
Cardiac Surgery re-alignment South Wales	(£1,500)	(£750)	(£750)	-	-£1,500	-
Mental Health Strategy - Reduce OOA & LOS	(£1,000)	(£500)	(£500)	-	-£1,000	-
NHS E Referral Management	(£1,000)	(£500)	-	£500	-£1,000	-
BCU Cardiac contract Rebasing	(£700)	(£350)	-	£350	-£700	-
Cystic Fibrosis - New contract model S Wales	(£550)	(£275)	(£275)	-	-£550	-
Cystic Fibrosis - New contract model N Wales	(£150)	(£75)	-	£75	-£150	-
Genetics - Repatriate send out tests phase 2	(£100)	(£50)	-	£50	-£100	-
Total Savings as per ICP	(£10,000)	(£5,000)	(£2,750)	£2,250	-£10,000	-

For ref: Prior year savings delivery -£9,601

The forecast position at month 6 **assumes delivery of the entire JCC savings target**. This includes the **£4.5m allocated to savings without specific projects at this point, which has been covered by recurring and non-recurring Developments slippage**.

Work is ongoing with commissioning teams to develop robust processes to monitor delivery; all identified savings schemes have a dedicated Executive, Planning and Finance lead to monitor and track delivery throughout the year. This will be closely monitored with the JCC Director team and reported transparently to Health Board Commissioners.

An Action Route to Breakeven has been produced with strands of work including analysing recent Funding Releases and Developments funding to identify any potential slippage, with Management Group and Joint Committee meetings to follow. Work will also continue in-year to mitigate overspends, and work towards a break-even position.

The ICP includes a **£10m savings target**, equivalent to **3%** of £330m influenceable cost base across drugs and devices, Independent Sector and NHS England referrals.

It should be noted that the expectation from Welsh Government set out in the funding allocation letter was a minimum of 2%.

At this stage, £5.5m has been identified as green/amber, with a **further £4.5m to be developed. This £4.5m is being covered by recurring and non-recurring Developments slippage.**

In addition, WAST are required to deliver a 2.2% savings target (c. £6.4m) to report a breakeven position against the funding provided (netted off against WAST contract baselines). This will be monitored closely and feedback will be provided to the Committee if there is any risk to delivery or required actions.

INCOME/EXPENDITURE ASSUMPTIONS

There are no notified disputes regarding the income assumptions related to the JCC IMTP. Invoices over 11 weeks in age detailed to aid LHB's in clearing them before arbitration dates:

- none

PUBLIC SECTOR PAYMENT COMPLIANCE

As at the end of Q2 2024/25 WHSSC had achieved **99.4% compliance for NHS invoices paid within 30 days by value and 96.9% by number.**

For non-NHS invoices WHSSC had achieved 98.5% in value for invoices paid within 30 days and 99.1% by number.

This data is updated on a quarterly basis; the next update will be provided following the end of Q3.

RESPONSES TO ACTION NOTES FROM WG MMR RESPONSES


- 1.4 Ensure a single signed narrative is provided as part of the MMR submissions - noted
- 3.4 C&VUHB contract - please note the Cardiff contract is agreed between JCC/C&VUHB, and their Board has formally approved it. A signed copy will be received shortly.
- 5.1 Update on the Route to Breakeven - the presentation to the NWJCC members on September 17th will be followed with an Options session on October 15th
- 5.2 Cardiac Surgery Phase 2 - the potential Savings cannot yet be quantified until the review is concluded, as fixed costs cannot be immediately released and will probably fall into 2025/26
- 5.3 The risks relating to the HPN homecare drugs and Gender spend have both been removed, as the overspends have been realised within the financial position

Note: the movements on MMR Tab B2 for M6 (lines 15 and 18) relate to an adjustment of our coding lookups.

CONFIRMATION OF REPORT

Abigail Harris

Interim Chief Commissioner



Stacey Taylor

Director of Finance & Information

NWJCC / JCC - NHS Wales Joint Commissioning Committee
ALAS - Artificial Limbs and Appliances Services
CAMHS - Child and Adolescent Mental Health Services
DDRC - Diving Diseases Research Centre
DRC - Direct Running Costs
EASC - Emergency Ambulance Services Committee (now part of NWJCC)
ED - Eating Disorders
EMRTS - Emergency Medical Retrieval & Transfer Service
ICD - Interventional Cardiac Devices
ICP - Integrated Commissioning Plan
IPC/IPFR - Individual Patient Commissioning / Funding Request
IVF - In Vitro Fertilisation
NCCU - National Collaborative Commissioning Unit
NHSE - NHS England
OOA - Out of Area
PETIC - Positron Emission Tomography Imaging Centre
PSPP - Public Sector Payment Compliance
SLA - Service Level Agreement
TAVI - Trans Aortic Valve Implant (Cardiology)
WAST - Welsh Ambulance Services Trust
WHSSC - Welsh Health Specialised Services Committee (now part of NWJCC)

ABUHB Commissioner Contribution to JCC

Budgeted Income £'000	EOYF £'000	Total £'000
£215,789	£990	£216,780

EOYF Variance as a % of Budgeted Income 0.46%


NHS Wales Breakdown

	YTD Variance £'000	EOYF Variance £'000
Cardiff & Vale	£1,239	£1,840
Swansea Bay	£118	£257
Betsi Cadwaladr	£20	£20
Aneurin Bevan	-	-
Cwm Taf Morgannwg	-	-
Hywel Dda	-	-
WAST	-	-
Velindre	(£136)	(£136)
Total	£1,242	£1,982

Breakdown of EOYF Variance by Area:

NHS Wales	IPFR	Savings	Renal	Direct Running Costs	IVF	Non Welsh SLA	Releases	Mental Health	Developments	Total
£1.982	£1.132	-	(£14)	(£35)	(£128)	(£138)	(£281)	(£665)	(£863)	£990

Top 15 Services by EOYF Variance £'000 - top 10 overspends and top 5 underspends



Comments/Notes:

Aneurin Bevan residents services come primarily from Cardiff & Vale UHB, NHS England and private providers in relation to Mental Health individual placements.

The current year-end forecast variance of £990k overspent includes the following main components:

- Cardiology through Cardiff & Vale - £124k overspent in total, made up of £761k on general Specialist Cardiology, and an underspend of £637k on AB Cardiology
- TAVI activity through Cardiff & Vale - £619k overspent in total, from a projected over-activity from the provider. A detailed SBAR and projections have been requested from the provider.
- HPN homecare drugs - overspend of £498k related to the newly procured contract
- ALAS services (wheelchairs and prosthetics) through Cardiff & Vale - £356k overspent; more detail has been requested from the provider
- Mental Health - overspends on Gender have been covered by significant underspends on Medium Secure Mental Health savings on enhanced observations and placements
- High cost drugs including ERT and NICE drugs, partially covered by drugs funding in the agreed ICP.

Please see the NWJCC risk-share tables for more details by individual lines.

BCUHB Commissioner Contribution to JCC

Budgeted Income £'000	EOYF £'000	Total £'000
£249,265	£1,332	£250,597
<i>EOYF Variance as a % of Budgeted Income</i>		0.53%


NHS Wales Breakdown

	YTD Variance £'000	EOYF Variance £'000
Aneurin Bevan	-	-
Betsi Cadwaladr	(£461)	(£225)
Cardiff & Vale	£344	£549
Cwm Taf Morgannwg	-	-
Hywel Dda	-	-
Swansea Bay	£100	£231
Velindre	-	-
WAST	-	-
Total	(£18)	£555

Breakdown of EOYF Variance by Area:

Non Welsh SLA	IPFR NHS Wales	IVF	Savings	Renal	Direct Running Costs	Releases	Mental Health	Developments	Total	
£1,183	£846	£555	£140	-	(£17)	(£43)	(£334)	(£390)	(£607)	£1,332

Top 15 Services by EOYF Variance £'000 - top 10 overspends and top 5 underspends



Comments/Notes:

Betsi Cadwaladr residents services come primarily from their own Health Board, NHS England and private providers in relation to Mental Health individual placements.

The current year-end forecast variance of £1,332k overspent includes the following main components:

- Walton - overspend of £2.2m forecast, from reverting back to a Cost & Volume basis.
- Liverpool Heart & Chest - overspend of £2.2m forecast, from increasing activity. Increasing Cardiology activity is following the trend in South Wales providers as well.
- ALAS services (wheelchairs and prosthetics) through Cardiff & Vale - £424k overspent; more detail has been requested from the provider as this line is risk-shared across all Health Boards, and therefore affecting BCUHB's financial position
- Mental Health - overspends on Gender have been covered by significant underspends on Medium Secure Mental Health savings on enhanced observations and placements
- High cost drugs including ERT and NICE drugs, partially covered by drugs funding in the agreed ICP.

Please see the NWJCC risk-share tables for more details by individual lines.

Commissioner Overview: CVUHB

Financial Year

Multiple selecti... ▾

Financial Month

6 ▾

CVUHB Commissioner Contribution to JCC

Budgeted Income £'000	EOYF £'000	Total £'000
£184,988	£661	£185,650

EOYF Variance as a % of Budgeted Income 0.36%


NHS Wales Breakdown

	YTD Variance £'000	EOYF Variance £'000
Aneurin Bevan	-	-
Betsi Cadwaladr	£17	£17
Cardiff & Vale	£790	£1,266
Cwm Taf Morgannwg	-	-
Hywel Dda	-	-
Swansea Bay	£111	£216
Velindre	(£99)	(£99)
WAST	-	-
Total	£819	£1,400

Breakdown of EOYF Variance by Area:

NHS Wales	IPFR	Savings	Renal	Direct Running Costs	Non Welsh SLA	Mental Health	IVF	Releases	Developments	Total
£1,400	£1,056	-	(£11)	(£33)	(£163)	(£201)	(£203)	(£238)	(£945)	£661

Top 15 Services by EOYF Variance £'000 - top 10 overspends and top 5 underspends



Comments/Notes:

Cardiff & Vale residents services come primarily from Cardiff & Vale UHB, NHS England and private providers in relation to Mental Health individual placements.

The current year-end forecast variance of £661k overspent includes the following main components:

- TAVI activity through Cardiff & Vale - £407k overspent in total, from a projected over-activity from the provider. A detailed SBAR and projections have been requested from the provider.
- HPN homecare drugs - overspend of £634k related to the newly procured contract
- ALAS services (wheelchairs and prosthetics) through Cardiff & Vale - £301k overspent; more detail has been requested from the provider
- Mental Health - overspends on Gender have been covered by significant underspends on Medium Secure Mental Health savings on enhanced observations and placements
- High cost drugs including ERT and NICE drugs, partially covered by drugs funding in the agreed ICP.

Please see the NWJCC risk-share tables for more details by individual lines.

CTMUHB Commissioner Contribution to JCC

Budgeted Income £'000	EOYF £'000	Total £'000
£160,723	£903	£161,626

EOYF Variance as a % of Budgeted Income **0.56%**


NHS Wales Breakdown

	YTD Variance	EOYF Variance
Aneurin Bevan	-	-
Betsi Cadwaladr	£15	£15
Cardiff & Vale	£692	£1,278
Cwm Taf Morgannwg	-	-
Hywel Dda	-	-
Swansea Bay	£169	£302
Velindre	(£96)	(£96)
WAST	-	-
Total	£780	£1,499

Breakdown of EOYF Variance by Area:

NHS Wales	IPFR	Savings	Renal	Direct Running Costs	IVF	Non Welsh SLA	Releases	Mental Health	Developments	Total
£1,499	£772	-	(£11)	(£26)	(£93)	(£150)	(£213)	(£220)	(£656)	£903

Top 15 Services by EOYF Variance £'000 - top 10 overspends and top 5 underspends



Comments/Notes:

Cwm Taf Morgannwg residents services come primarily from Cardiff & Vale UHB, Swansea Bay UHB, NHS England and private providers in relation to Mental Health individual placements.

The current year-end forecast variance of £903k overspent includes the following main components:

- HPN homecare drugs - overspend of £441k related to the newly procured contract
- ALAS services (wheelchairs and prosthetics) through Cardiff & Vale - £270k overspent; more detail has been requested from the provider
- Mental Health - overspends on Gender have been covered by significant underspends on Medium Secure Mental Health savings on enhanced observations and placements
- High cost drugs including ERT and NICE drugs , partially covered by drugs funding agreed in the ICP.

Please see the NWJCC risk-share tables for more details by individual lines.

HDUHB Commissioner Contribution to JCC

Budgeted Income £'000	EOYF £'000	Total £'000
£135,277	£791	£136,069

EOYF Variance as a % of Budgeted Income **0.58%**


NHS Wales Breakdown

	YTD Variance £'000	EOYF Variance £'000
Aneurin Bevan	-	-
Betsi Cadwaladr	£13	£13
Cardiff & Vale	£343	£694
Cwm Taf Morgannwg	-	-
Hywel Dda	-	-
Swansea Bay	£667	£822
Velindre	(£5)	(£5)
WAST	-	-
Total	£1,018	£1,524

Breakdown of EOYF Variance by Area:

NHS Wales	IPFR	Savings	Renal	Direct Running Costs	IVF	Non Welsh SLA	Releases	Mental Health	Developments	Total
£1,524	£388	-	(£10)	(£21)	(£83)	(£123)	(£184)	(£190)	(£510)	£791

Top 15 Services by EOYF Variance £'000 - top 10 overspends and top 5 underspends



Comments/Notes:

Hywel Dda residents services come primarily from Cardiff & Vale UHB, Swansea Bay UHB, NHS England and private providers in relation to Mental Health individual placements.

The current year-end forecast variance of £791k overspent includes the following main components:

- TAVI activity through Swansea Bay - £529k overspent in total, from TAVI contract increases as agreed through Management Group in December 2023. Savings from the Cardiac Surgery rebasing are expected to help cover this spend, but is currently tied up in fixed costs and will be considered in the Phase 2 part of this project.
- ALAS services (wheelchairs and prosthetics) through Cardiff & Vale - £233k overspent; more detail has been requested from the provider
- HPN homecare drugs - overspend of £156k related to the newly procured contract
- High cost drugs including ERT and NICE drugs, partially covered by drugs funding agreed in the ICP.

Please see the NWJCC risk-share tables for more details by individual lines.

PTHB Commissioner Contribution to JCC

Budgeted Income £'000	EOYF £'000	Total £'000
£56,600	£279	£56,879

EOYF Variance as a % of Budgeted Income **0.49%**


NHS Wales Breakdown

	YTD Variance £'000	EOYF Variance £'000
Aneurin Bevan	-	-
Betsi Cadwaladr	£4	£5
Cardiff & Vale	£141	£222
Cwm Taf Morgannwg	-	-
Hywel Dda	-	-
Swansea Bay	£41	£72
Velindre	(£7)	(£7)
WAST	-	-
Total	£180	£292

Breakdown of EOYF Variance by Area:

NHS Wales	IPFR	Non Welsh SLA	IVF	Savings	Renal	Direct Running Costs	Releases	Developments	Mental Health	Total
£292	£245	£214	£12	-	(£3)	(£9)	(£63)	(£150)	(£257)	£279

Top 15 Services by EOYF Variance £'000 - top 10 overspends and top 5 underspends



Comments/Notes:

Powys residents services come primarily from Cardiff & Vale UHB, Swansea Bay UHB, NHS England and private providers in relation to Mental Health individual placements.

The current year-end forecast variance of £279k overspent includes the following main components:

- NHS England - Birmingham Women & Children overspend of £158k.
- NHS England - Heart of England overspend of £151k.
- ALAS services (wheelchairs and prosthetics) through Cardiff & Vale - £80k overspent; more detail has been requested from the provider
- HPN homecare drugs - overspend of £58k related to the newly procured contract
- Mental Health - overspends on Gender have been covered by significant underspends on Medium Secure Mental Health savings on enhanced observations and placements
- High cost drugs including ERT and NICE drugs, partially covered by drugs funding agreed in the ICP.

Please see the NWJCC risk-share tables for more details by individual lines.

SBUHB Commissioner Contribution to JCC

Budgeted Income £'000	EOYF £'000	Total £'000
£138,887	£683	£139,570

EOYF Variance as a % of Budgeted Income 0.49%


NHS Wales Breakdown

	YTD Variance £'000	EOYF Variance £'000
Aneurin Bevan	-	-
Betsi Cadwaladr	£13	£13
Cardiff & Vale	£368	£750
Cwm Taf Morgannwg	-	-
Hywel Dda	-	-
Swansea Bay	£801	£939
Velindre	(£2)	(£2)
WAST	-	-
Total	£1,180	£1,700

Breakdown of EOYF Variance by Area:

NHS Wales	IPFR	Savings	Renal	Direct Running Costs	IVF	Releases	Non Welsh SLA	Mental Health	Developments	Total
£1,700	£426	-	(£9)	(£23)	(£117)	(£186)	(£187)	(£363)	(£557)	£683

Top 15 Services by EOYF Variance £'000 - top 10 overspends and top 5 underspends



Comments/Notes:

Swansea Bay residents services come primarily from Cardiff & Vale UHB, Swansea Bay UHB, NHS England and private providers in relation to Mental Health individual placements.

The current year-end forecast variance of £683k overspent includes the following main components:

- TAVI activity through Swansea Bay - £679k overspent in total, from TAVI contract increases as agreed through Management Group in December 2023. Savings from the Cardiac Surgery rebasing are expected to help cover this spend, but is currently tied up in fixed costs and will be considered in the Phase 2 part of this project. Projections have been requested from the provider for the 24/25 forecasts.
- ALAS services (wheelchairs and prosthetics) through Cardiff & Vale - £236k overspent; more detail has been requested from the provider
- HPN homecare drugs - overspend of £108k related to the newly procured contract
- Mental Health - overspends on Gender have been covered by significant underspends on Medium Secure Mental Health savings on enhanced observations and placements
- High cost drugs including ERT and NICE drugs, partially covered by drugs funding agreed in the ICP.

Please see the NWJCC risk-share tables for more details by individual lines.